866-997-4948(US-Canada Toll Free)

Global Urological Cancer Drugs Sales Market Report 2017

Published By :

QYResearch

Published Date : Feb 2017

Category :

Cancer

No. of Pages : 128 Pages

Notes:
Sales, means the sales volume of Urological Cancer Drugs
Revenue, means the sales value of Urological Cancer Drugs

This report studies sales (consumption) of Urological Cancer Drugs in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A.
Tolmar Inc

Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Urological Cancer Drugs in these regions, from 2011 to 2021 (forecast), like
United States
China
Europe
Japan
Southeast Asia
India
Split by product Types, with sales, revenue, price and gross margin, market share and growth rate of each type, can be divided into
Xofigo (Radium Ra 223 Dichloride)
Jevtana (Cabazitaxel)
Inlyta (Axitinib)
Votrient (Pazopanib Hydrochloride)
Sutent (Sunitinib Malate)
Zytiga (Abiraterone Acetate)
Xtandi (Enzalutamide)
Opdivo (Nivolumab)
Provenge (Sipuleucel-T)
Split by applications, this report focuses on sales, market share and growth rate of Urological Cancer Drugs in each application, can be divided into
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular Cancer

Table of Contents

Global Urological Cancer Drugs Sales Market Report 2017
1 Urological Cancer Drugs Overview
1.1 Product Overview and Scope of Urological Cancer Drugs
1.2 Classification of Urological Cancer Drugs
1.2.1 Xofigo (Radium Ra 223 Dichloride)
1.2.2 Jevtana (Cabazitaxel)
1.2.3 Inlyta (Axitinib)
1.2.4 Votrient (Pazopanib Hydrochloride)
1.2.5 Sutent (Sunitinib Malate)
1.2.6 Zytiga (Abiraterone Acetate)
1.2.7 Xtandi (Enzalutamide)
1.2.8 Opdivo (Nivolumab)
1.2.9 Provenge (Sipuleucel-T)
1.3 Application of Urological Cancer Drugs
1.3.1 Prostate Cancer
1.3.2 Bladder Cancer
1.3.3 Kidney Cancer
1.3.4 Testicular Cancer
1.4 Urological Cancer Drugs Market by Regions
1.4.1 United States Status and Prospect (2012-2022)
1.4.2 China Status and Prospect (2012-2022)
1.4.3 Europe Status and Prospect (2012-2022)
1.4.4 Japan Status and Prospect (2012-2022)
1.4.5 Southeast Asia Status and Prospect (2012-2022)
1.4.6 India Status and Prospect (2012-2022)
1.5 Global Market Size (Value and Volume) of Urological Cancer Drugs (2012-2022)
1.5.1 Global Urological Cancer Drugs Sales and Growth Rate (2012-2022)
1.5.2 Global Urological Cancer Drugs Revenue and Growth Rate (2012-2022)

2 Global Urological Cancer Drugs Competition by Manufacturers, Type and Application
2.1 Global Urological Cancer Drugs Market Competition by Manufacturers
2.1.1 Global Urological Cancer Drugs Sales and Market Share of Key Manufacturers (2012-2017)
2.1.2 Global Urological Cancer Drugs Revenue and Share by Manufacturers (2012-2017)
2.2 Global Urological Cancer Drugs (Volume and Value) by Type
2.2.1 Global Urological Cancer Drugs Sales and Market Share by Type (2012-2017)
2.2.2 Global Urological Cancer Drugs Revenue and Market Share by Type (2012-2017)
2.3 Global Urological Cancer Drugs (Volume and Value) by Regions
2.3.1 Global Urological Cancer Drugs Sales and Market Share by Regions (2012-2017)
2.3.2 Global Urological Cancer Drugs Revenue and Market Share by Regions (2012-2017)
2.4 Global Urological Cancer Drugs (Volume) by Application

3 United States Urological Cancer Drugs (Volume, Value and Sales Price)
3.1 United States Urological Cancer Drugs Sales and Value (2012-2017)
3.1.1 United States Urological Cancer Drugs Sales and Growth Rate (2012-2017)
3.1.2 United States Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
3.1.3 United States Urological Cancer Drugs Sales Price Trend (2012-2017)
3.2 United States Urological Cancer Drugs Sales and Market Share by Manufacturers
3.3 United States Urological Cancer Drugs Sales and Market Share by Type
3.4 United States Urological Cancer Drugs Sales and Market Share by Application

4 China Urological Cancer Drugs (Volume, Value and Sales Price)
4.1 China Urological Cancer Drugs Sales and Value (2012-2017)
4.1.1 China Urological Cancer Drugs Sales and Growth Rate (2012-2017)
4.1.2 China Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
4.1.3 China Urological Cancer Drugs Sales Price Trend (2012-2017)
4.2 China Urological Cancer Drugs Sales and Market Share by Manufacturers
4.3 China Urological Cancer Drugs Sales and Market Share by Type
4.4 China Urological Cancer Drugs Sales and Market Share by Application

5 Europe Urological Cancer Drugs (Volume, Value and Sales Price)
5.1 Europe Urological Cancer Drugs Sales and Value (2012-2017)
5.1.1 Europe Urological Cancer Drugs Sales and Growth Rate (2012-2017)
5.1.2 Europe Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
5.1.3 Europe Urological Cancer Drugs Sales Price Trend (2012-2017)
5.2 Europe Urological Cancer Drugs Sales and Market Share by Manufacturers
5.3 Europe Urological Cancer Drugs Sales and Market Share by Type
5.4 Europe Urological Cancer Drugs Sales and Market Share by Application

6 Japan Urological Cancer Drugs (Volume, Value and Sales Price)
6.1 Japan Urological Cancer Drugs Sales and Value (2012-2017)
6.1.1 Japan Urological Cancer Drugs Sales and Growth Rate (2012-2017)
6.1.2 Japan Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
6.1.3 Japan Urological Cancer Drugs Sales Price Trend (2012-2017)
6.2 Japan Urological Cancer Drugs Sales and Market Share by Manufacturers
6.3 Japan Urological Cancer Drugs Sales and Market Share by Type
6.4 Japan Urological Cancer Drugs Sales and Market Share by Application
7 Southeast Asia Urological Cancer Drugs (Volume, Value and Sales Price)
7.1 Southeast Asia Urological Cancer Drugs Sales and Value (2012-2017)
7.1.1 Southeast Asia Urological Cancer Drugs Sales and Growth Rate (2012-2017)
7.1.2 Southeast Asia Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
7.1.3 Southeast Asia Urological Cancer Drugs Sales Price Trend (2012-2017)
7.2 Southeast Asia Urological Cancer Drugs Sales and Market Share by Manufacturers
7.3 Southeast Asia Urological Cancer Drugs Sales and Market Share by Type
7.4 Southeast Asia Urological Cancer Drugs Sales and Market Share by Application
8 India Urological Cancer Drugs (Volume, Value and Sales Price)
8.1 India Urological Cancer Drugs Sales and Value (2012-2017)
8.1.1 India Urological Cancer Drugs Sales and Growth Rate (2012-2017)
8.1.2 India Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
8.1.3 India Urological Cancer Drugs Sales Price Trend (2012-2017)
8.2 India Urological Cancer Drugs Sales and Market Share by Manufacturers
8.3 India Urological Cancer Drugs Sales and Market Share by Type
8.4 India Urological Cancer Drugs Sales and Market Share by Application

9 Global Urological Cancer Drugs Manufacturers Analysis
9.1 Novartis
9.1.1 Company Basic Information, Manufacturing Base and Competitors
9.1.2 Urological Cancer Drugs Product Type, Application and Specification
9.1.2.1 Xofigo (Radium Ra 223 Dichloride)
9.1.2.2 Jevtana (Cabazitaxel)
9.1.3 Novartis Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
9.1.4 Main Business/Business Overview
9.2 Pfizer
9.2.1 Company Basic Information, Manufacturing Base and Competitors
9.2.2 Urological Cancer Drugs Product Type, Application and Specification
9.2.2.1 Xofigo (Radium Ra 223 Dichloride)
9.2.2.2 Jevtana (Cabazitaxel)
9.2.3 Pfizer Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
9.2.4 Main Business/Business Overview
9.3 Johnson & Johnson
9.3.1 Company Basic Information, Manufacturing Base and Competitors
9.3.2 Urological Cancer Drugs Product Type, Application and Specification
9.3.2.1 Xofigo (Radium Ra 223 Dichloride)
9.3.2.2 Jevtana (Cabazitaxel)
9.3.3 Johnson & Johnson Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
9.3.4 Main Business/Business Overview
9.4 AstraZeneca
9.4.1 Company Basic Information, Manufacturing Base and Competitors
9.4.2 Urological Cancer Drugs Product Type, Application and Specification
9.4.2.1 Xofigo (Radium Ra 223 Dichloride)
9.4.2.2 Jevtana (Cabazitaxel)
9.4.3 AstraZeneca Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
9.4.4 Main Business/Business Overview
9.5 Astellas
9.5.1 Company Basic Information, Manufacturing Base and Competitors
9.5.2 Urological Cancer Drugs Product Type, Application and Specification
9.5.2.1 Xofigo (Radium Ra 223 Dichloride)
9.5.2.2 Jevtana (Cabazitaxel)
9.5.3 Astellas Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
9.5.4 Main Business/Business Overview
9.6 Bristol-Myers Squibb
9.6.1 Company Basic Information, Manufacturing Base and Competitors
9.6.2 Urological Cancer Drugs Product Type, Application and Specification
9.6.2.1 Xofigo (Radium Ra 223 Dichloride)
9.6.2.2 Jevtana (Cabazitaxel)
9.6.3 Bristol-Myers Squibb Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
9.6.4 Main Business/Business Overview
9.7 Abbott Laboratories
9.7.1 Company Basic Information, Manufacturing Base and Competitors
9.7.2 Urological Cancer Drugs Product Type, Application and Specification
9.7.2.1 Xofigo (Radium Ra 223 Dichloride)
9.7.2.2 Jevtana (Cabazitaxel)
9.7.3 Abbott Laboratories Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
9.7.4 Main Business/Business Overview
9.8 Celgene Corporation
9.8.1 Company Basic Information, Manufacturing Base and Competitors
9.8.2 Urological Cancer Drugs Product Type, Application and Specification
9.8.2.1 Xofigo (Radium Ra 223 Dichloride)
9.8.2.2 Jevtana (Cabazitaxel)
9.8.3 Celgene Corporation Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
9.8.4 Main Business/Business Overview
9.9 Dendreon Corporation
9.9.1 Company Basic Information, Manufacturing Base and Competitors
9.9.2 Urological Cancer Drugs Product Type, Application and Specification
9.9.2.1 Xofigo (Radium Ra 223 Dichloride)
9.9.2.2 Jevtana (Cabazitaxel)
9.9.3 Dendreon Corporation Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
9.9.4 Main Business/Business Overview
9.10 Ferring Pharmaceuticals
9.10.1 Company Basic Information, Manufacturing Base and Competitors
9.10.2 Urological Cancer Drugs Product Type, Application and Specification
9.10.2.1 Xofigo (Radium Ra 223 Dichloride)
9.10.2.2 Jevtana (Cabazitaxel)
9.10.3 Ferring Pharmaceuticals Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
9.10.4 Main Business/Business Overview
9.11 GlaxoSmithKline
9.12 Indevus Pharmaceuticals Inc
9.13 Ipsen
9.14 Roche Healthcare
9.15 Sanofi S.A.
9.16 Tolmar Inc

10 Urological Cancer Drugs Maufacturing Cost Analysis
10.1 Urological Cancer Drugs Key Raw Materials Analysis
10.1.1 Key Raw Materials
10.1.2 Price Trend of Key Raw Materials
10.1.3 Key Suppliers of Raw Materials
10.1.4 Market Concentration Rate of Raw Materials
10.2 Proportion of Manufacturing Cost Structure
10.2.1 Raw Materials
10.2.2 Labor Cost
10.2.3 Manufacturing Process Analysis of Urological Cancer Drugs
10.3 Manufacturing Process Analysis of Urological Cancer Drugs

11 Industrial Chain, Sourcing Strategy and Downstream Buyers
11.1 Urological Cancer Drugs Industrial Chain Analysis
11.2 Upstream Raw Materials Sourcing
11.3 Raw Materials Sources of Urological Cancer Drugs Major Manufacturers in 2015
11.4 Downstream Buyers

12 Marketing Strategy Analysis, Distributors/Traders
12.1 Marketing Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.1.3 Marketing Channel Development Trend
12.2 Market Positioning
12.2.1 Pricing Strategy
12.2.2 Brand Strategy
12.2.3 Target Client
12.3 Distributors/Traders List

13 Market Effect Factors Analysis
13.1 Technology Progress/Risk
13.1.1 Substitutes Threat
13.1.2 Technology Progress in Related Industry
13.2 Consumer Needs/Customer Preference Change
13.3 Economic/Political Environmental Change

14 Global Urological Cancer Drugs Market Forecast (2017-2022)
14.1 Global Urological Cancer Drugs Sales, Revenue and Price Forecast (2017-2022)
14.1.1 Global Urological Cancer Drugs Sales and Growth Rate Forecast (2017-2022)
14.1.2 Global Urological Cancer Drugs Revenue and Growth Rate Forecast (2017-2022)
14.1.3 Global Urological Cancer Drugs Price and Trend Forecast (2017-2022)
14.2 Global Urological Cancer Drugs Sales, Revenue and Growth Rate Forecast by Regions (2017-2022)
14.2.1 United States Urological Cancer Drugs Sales, Revenue and Growth Rate Forecast (2017-2022)
14.2.2 China Urological Cancer Drugs Sales, Revenue and Growth Rate Forecast (2017-2022)
14.2.3 Europe Urological Cancer Drugs Sales, Revenue and Growth Rate Forecast (2017-2022)
14.2.4 Japan Urological Cancer Drugs Sales, Revenue and Growth Rate Forecast (2017-2022)
14.2.5 Southeast Asia Urological Cancer Drugs Sales, Revenue and Growth Rate Forecast (2017-2022)
14.2.6 India Urological Cancer Drugs Sales, Revenue and Growth Rate Forecast (2017-2022)
14.3 Global Urological Cancer Drugs Sales, Revenue and Price Forecast by Type (2017-2022)
14.4 Global Urological Cancer Drugs Sales Forecast by Application (2017-2022)

15 Research Findings and Conclusion

16 Appendix
Methodology
Analyst Introduction
Data Source


Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *